CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Brief Behavioral Activation with Mental ImageryWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug1766 Minimal Attention Control Intervention Wiki 1.00

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D003863 Depression, NIH 0.14

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Behavioral Activation and Mental Imagery Delivered Via Telephone for the Treatment of Depressive Symptoms in Older Individuals in Isolation During Covid-19: A Randomized Clinical Trial

This research study is designed to investigate the effects of a brief psychological intervention for improving depressed mood in older individuals (65 years and older) in isolation during the Coronavirus (COVID-19) pandemic. The treatment is delivered by telephone and consists of four weekly individual sessions. Two therapeutic methods are used in combination during this intervention: Behavioral activation (BA) and Mental Imagery (MI). BA involves identifying and scheduling enjoyable and meaningful activities to improve mood and reduce social isolation. To enhance BA efficacy and adherence, MI is paired with BA as MI is known to activate emotion and motivation. The MI intervention in this study involves having participants imagine, in vivid sensory detail, engaging in some of the activities that are scheduled during BA. Approximately 154 individuals will participate in the study. Half of the participants will be randomised to start the intervention immediately, while the other half of the participants will be randomized to a control group receiving the intervention after 4 weeks. This procedure makes it possible to evaluate the effects of the treatment while not disadvantaging participants randomized to the control group. Participants will be asked to fill in questionnaires before, during (at the end of each intervention week), and after treatment (or waiting period for the control group). Questionnaires will also be sent 1-, 3- and 6 months after treatment to follow up on the results. A smaller group of participants (10-15) will be asked to participate in a more detailed interview about how they experienced the treatment.

NCT04508868 Depression Depressive Symptoms Behavioral: Brief Behavioral Activation with Mental Imagery Behavioral: Minimal Attention Control Intervention
MeSH:Depression

Primary Outcomes

Description: MADRS-S is a nine-item questionnaire used to measure severity of depression. The score ranges from 0-54.

Measure: Change from baseline in depressive symptoms using the Montgomery-Asberg Depression Rating Scale, MADRS-S

Time: Baseline; Intervention Week 1; Intervention Week 2; Intervention Week 3; Intervention Week 4; 1 month post-intervention; 3 months post-intervention; 6 months post-intervention.

Secondary Outcomes

Description: GDS-15 is a 15-item questionnaire used to identify depression in the elderly. The score ranges from 0-15.

Measure: Change from baseline in depressive symptoms using the Geriatric Depression Rating Scale 15, GDS-15

Time: Baseline; Intervention Week 4; 1 month post-intervention; 3 months post-intervention; 6 months post-intervention.

Description: PHQ-9 is a nine-item questionnaire used to identify depression as well as measuring severity of depression. The score ranges from 0-27.

Measure: Change from baseline in depressive symptoms using the Patient Health Questionnaire 9, PHQ-9

Time: Baseline; Intervention Week 4; 1 month post-intervention; 3 months post-intervention; 6 months post-intervention.

Description: MINI is a structured clinical interview used to assess the presence/absence of common psychiatric disorders.

Measure: Change in depression diagnosis assessed using the Mini International Neuropsychiatric Interview, MINI

Time: Baseline; Intervention Week 4.

Description: GAD-7 is a seven-item questionnaire used to identify generalized anxiety disorder as well as measuring severity of anxiety symptoms. The score ranges from 0-21.

Measure: Change from baseline in anxiety symptoms using the Generalized Anxiety Disorder 7-item, GAD-7

Time: Baseline; Intervention Week 4; 1 month post-intervention; 3 months post-intervention; 6 months post-intervention.

Description: BADS-SF is a nine-item questionnaire used to measure changes in avoidance and activation. The score ranges from 0-54.

Measure: Change from baseline in behavioral activation using The Behavioral Activation for Depression Scale - Short Form, BADS-SF

Time: Baseline; Intervention Week 4; 1 month post-intervention; 3 months post-intervention; 6 months post-intervention.

Description: WHODAS-12 is a 12-item questionnaire used to assess disability due to health conditions. The total score ranges from 0-48.

Measure: Change from baseline in health and disability using The WHO Disability Assessment Schedule 12-item, WHODAS

Time: Baseline; Intervention Week 4; 1 month post-intervention; 3 months post-intervention; 6 months post-intervention.

Description: NEQ is a 20-item questionnaire used to assess adverse and unwanted effects of psychological treatments.

Measure: Adverse and unwanted effects of the experimental intervention using the Negative Effects Questionnaire, NEQ

Time: Experimental Intervention Week 4.

Description: Psi-Q is a 35-item questionnaire assessing the vividness of mental imagery. In this study we plan to use the visual subscale with five items, with a total score ranging from 0-50.

Measure: Mental imagery is assessed at baseline using the Plymouth Sensory Imagery Questionnaire, Psi-Q

Time: Baseline; Intervention Week 4.

No related HPO nodes (Using clinical trials)